Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1134

Sort by

Sort Order Select

Journal Articles

Adhesion to fibronectin via α5β1 integrin supports expansion of the megakaryocyte lineage in primary myelofibrosis

Shinobu Matsuura, Cristal Reyna Thompson, Seng Kah Ng, Christina Marie Ward, Aikaterini Karagianni, Carla Mazzeo, Alessandro Malara, Alessandra Balduini, Katya Ravid

Blood (2020) 135 (25): 2286–2291.

https://doi.org/10.1182/blood.2019004230

Published: 2020

Includes: Supplemental data

Journal Articles

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

Jessica L. Bridgford, Su Min Lee, Christine M. M. Lee, Paola Guglielmelli, Elisa Rumi, Daniela Pietra, Stephen Wilcox, Yash Chhabra, Alan F. Rubin, Mario Cazzola, Alessandro M. Vannucchi, Andrew J. Brooks, Matthew E. Call, Melissa J. Call

Blood (2020) 135 (4): 287–292.

https://doi.org/10.1182/blood.2019002561

Published: 2020

Includes: Supplemental data

Journal Articles

Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET)

Paula De Melo Campos, MD, Katia B Pagnano, MD PhD, Rubia Mancuso, Francisco Breno S. Teófilo, Juan L Coelho-Silva, BSc, MSc, Fernanda I Della Via, MSc, Leandro Luiz Lopes Freitas, MD PhD, Hernandes F. Carvalho, PhD, Fernando Ferreira Costa, MD PhD, Fabiola Traina, MD PhD, Sara T Olalla Saad, PhD

Blood (2019) 134 (Supplement_1): 554.

https://doi.org/10.1182/blood-2019-130648

Published: 2019

Journal Articles

Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF)

Mirko Farina, MD, Simona Bernardi, PhD, Nicola Polverelli, Camilla Zanaglio, PhD, Michele Malagola, MD, Federica Re, Federica Cattina, MD PhD, Mariella D'Adda, MD, Giuseppe Rossi, Tatiana Zollner, MD, Andrew Dunbar, MD, Ross L. Levine, MD, Domenico Russo, MD

Blood (2019) 134 (Supplement_1): 1684.

https://doi.org/10.1182/blood-2019-127451

Published: 2019

Journal Articles

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Alessandro Malara, PhD, Cristian Gruppi, PhD, Margherita Massa, Vittorio Rosti, MD, Giovanni Barosi, Alessandra Balduini, MD

Blood (2019) 134 (Supplement_1): 1688.

https://doi.org/10.1182/blood-2019-130735

Published: 2019

Journal Articles

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

Paola Guglielmelli, MD PhD, Alessandra Carobbio, BSc, Elisa Rumi, MD, Valerio De Stefano, MD, Lara Mannelli, MD, Francesco Mannelli, MD, Giada Rotunno, PhD, Giacomo Coltro, MD, Silvia Betti, MD PhD, Chiara Cavalloni, MD, Maria Chiara Finazzi, MD, Juergen Thiele, MD PhD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD

Blood (2019) 134 (Supplement_1): 1657.

https://doi.org/10.1182/blood-2019-124302

Published: 2019

Journal Articles

Homozygosity for -2518 G Allele Variant of MCP-1 Predisposes to Adverse Presentation and Outcome in Primary Myelofibrosis

Elena Masselli, MD, Cecilia Carubbi, PhD, Giulia Pozzi, MS, Antonio Percesepe, MD PhD, Rita Campanelli, Laura Villani, Giuliana Gobbi, PhD, Vittorio Rosti, MD, Margherita Massa, Giovanni Barosi, Marco Vitale, MD

Blood (2019) 134 (Supplement_1): 1689.

https://doi.org/10.1182/blood-2019-122750

Published: 2019

Journal Articles

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

Shunichiro Yasuda, MD, Satoru Aoyama, MD, Ryoto Yoshimoto, Student, Watanabe Daisuke, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Kouhei Yamamoto, Takeo Fujiwara, MD, Yoko Edahiro, MD PhD, Marito Araki, PhD, Norio Komatsu, MD PhD, Tetsuya Fukuda, MD PhD, Ayako Arai, MD PhD, Osamu Miura, MD, PhD, Norihiko Kawamata

Blood (2019) 134 (Supplement_1): 1690.

https://doi.org/10.1182/blood-2019-122652

Published: 2019

Journal Articles

Real World Data on Obstetric (OC) and Maternal Complications (MC) Occurring in a Cohort of Patients with Ph Negative Myeloproliferative Neoplasms (MPN): Argentinian Multicentric Study

Blood (2019) 134 (Supplement_1): 1669.

https://doi.org/10.1182/blood-2019-131778

Published: 2019

Journal Articles

Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Undergoing a Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Jeremy Johnson, PharmD, PhD, Jaime Holden, BFA, Paulina Lewkowski, BS, Iryna Mialik, AS, John P Galvin, MDMS,MPH, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 1980.

https://doi.org/10.1182/blood-2019-131886

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation Combined with Mesenchymal Stem Cells Transfusion in Primary Myelofibrosis-a Single-Center Retrospective Study

Qingyuan Wang, MD, Limin Liu, MD PhD, Huifen Zhou, Miao Miao, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 2054.

https://doi.org/10.1182/blood-2019-130572

Published: 2019

Journal Articles

The Pro-Adhesive and Reduced Angiogenic Properties of Endothelial Colony Forming Cells (ECFC) from JAK2 V617F MPN Patients Are Not Related to the Expression of the JAK2 mutation in These Cells: A Potential Role of ADAM17

Bruno Kosa Lino Duarte, Stephanie Ospina-Prieto, PhD, Lucia Helena Siqueira, Jessica O F Guanaes, MSc, Fernando Ferreira Costa, MD PhD, Margareth C Ozelo, MD PhD

Blood (2019) 134 (Supplement_1): 3618.

https://doi.org/10.1182/blood-2019-131488

Published: 2019

Journal Articles

Under Reporting of Patient Reported Outcomes (PROs) in Myeloproliferative Neoplasm (MPN) Clinical Trials

Anthony J Messina, MSc, Quentin E O'Brien, MPH, Vasily Andrianov, MD, Keren R. Moss, MD, Laura Vidal, MD, Liat Vidal-Fisher, MD MSc

Blood (2019) 134 (Supplement_1): 4754.

https://doi.org/10.1182/blood-2019-128741

Published: 2019

Journal Articles

Elevated Plasma sIL-2Rα Levels in Primary Myelofibrosis Play a Distinct Role on Disease Progression in JAK2V617F and Calr Mutants

Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Mara De Amici, Carlotta Abbà, MSc, Gianluca Viarengo, Laura Villani, Margherita Massa, Vittorio Rosti, MD

Blood (2019) 134 (Supplement_1): 1678.

https://doi.org/10.1182/blood-2019-125531

Published: 2019

Journal Articles

STAT1 Transcriptional Response Predicts Molecular Responses of PB-Derived Clonogenic Cells from MPN Patients to Interferon Alpha

Milena Kalmer, MSc, Kristina Feldberg, Deniz Gezer, Susanne Isfort, Tim H Brümmendorf, MD, Nicolas Chatain, Steffen Koschmieder

Blood (2019) 134 (Supplement_1): 1679.

https://doi.org/10.1182/blood-2019-122676

Published: 2019

Journal Articles

Clinical Features of Children with Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in Japan: Retrospective Nationwide Survey

Hisashi Ishida, MD PhD, Takeo Sarashina, MD PhD, Risa Matsumura, Katsutsugu Umeda, MD, PhD, Tetsuo Mitsui, MD PhD, Naoto Fujita, MD PhD, Daisuke Tomizawa, MD PhD, Kevin Y Urayama, PhD MPH, Yasushi Ishida, MD PhD, Takashi Taga, MD PhD, Masatoshi Takagi, MD PhD, Souichi Adachi, MD PhD, Atsushi Manabe, MD PhD, Toshihiko Imamura, MD PhD, Katsuyoshi Koh, MD, Akira Shimada, MD PhD

Blood (2019) 134 (Supplement_1): 2958.

https://doi.org/10.1182/blood-2019-123429

Published: 2019

Journal Articles

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

Tobias Ronny Haage, MD, Andreas Johann Müller, Priyadharshini Arunachalam, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2965.

https://doi.org/10.1182/blood-2019-122660

Published: 2019

Journal Articles

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Peter Müller, PhD, Bärbel Edelmann-Stephan, PhD, Fabian Richter, PhD, Klaus Pfizenmaier, PhD, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2966.

https://doi.org/10.1182/blood-2019-127997

Published: 2019

Journal Articles

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Andrew Sochacki, MD, Cosmin Adrian Bejan, PhD, Shilin Zhao, PhD, Travis Spaulding, MD, Shannon Stockton, MD, Alexander Silver, Dixon Dorand, MD PhD, Siwei Zhang, PhD, Thomas Stricker, MD PhD, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2959.

https://doi.org/10.1182/blood-2019-121513

Published: 2019

Journal Articles

Germline Mutations Predispose to Familial Myeloproliferative Neoplasms

Stephanie Berg, DO, Manuel O. Diaz, MD, Sucha Nand, MD, Jiwang Zhang, MD

Blood (2019) 134 (Supplement_1): 2969.

https://doi.org/10.1182/blood-2019-124805

Published: 2019

NARROW

Adhesion to fibronectin via α5β1 integrin supports expansion of the megakaryocyte lineage in primary myelofibrosis

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET)

Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF)

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

Homozygosity for -2518 G Allele Variant of MCP-1 Predisposes to Adverse Presentation and Outcome in Primary Myelofibrosis

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

Real World Data on Obstetric (OC) and Maternal Complications (MC) Occurring in a Cohort of Patients with Ph Negative Myeloproliferative Neoplasms (MPN): Argentinian Multicentric Study

Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Undergoing a Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan

Allogeneic Stem Cell Transplantation Combined with Mesenchymal Stem Cells Transfusion in Primary Myelofibrosis-a Single-Center Retrospective Study

The Pro-Adhesive and Reduced Angiogenic Properties of Endothelial Colony Forming Cells (ECFC) from JAK2 V617F MPN Patients Are Not Related to the Expression of the JAK2 mutation in These Cells: A Potential Role of ADAM17

Under Reporting of Patient Reported Outcomes (PROs) in Myeloproliferative Neoplasm (MPN) Clinical Trials

Elevated Plasma sIL-2Rα Levels in Primary Myelofibrosis Play a Distinct Role on Disease Progression in JAK2V617F and Calr Mutants

STAT1 Transcriptional Response Predicts Molecular Responses of PB-Derived Clonogenic Cells from MPN Patients to Interferon Alpha

Clinical Features of Children with Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in Japan: Retrospective Nationwide Survey

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Germline Mutations Predispose to Familial Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only